Figure 2.
WHO22 and ICC22 classification criteria analysis for WHOest, WHOnew, and ICCnew cases. (A) Overlap between the reclassified WHOnew and ICCnew cohorts, with the ICCnew cohort being a subgroup of the WHOnew cohort. (B) Overlap between established CMML cases after ICC22 (ICCest) and after WHO22 (WHOest) diagnosis update. (C-F) Classification criteria analysis in the WHOest (subdivided into MD-CMML and MP-CMML), WHOnew, and ICCnew cohorts. (C) Number of cytopenic lineages in the PB. (D) Evidence of clonality. Patients were separated into “no clonality” (maximal VAF <2% of myeloid malignancy associated mutations), VAF between 2% and 10%, and VAF >10% or karyotypical alteration. Only data of patients with ≥10 genes sequenced are shown. (E) Number of dysplastic lineages in the BM. (F) Age-adjusted BM cellularity.